Tumor genomic profiling with Agilent SureSelect cancer assays

Agilent SureSelect cancer assays are a portfolio of targeted resequencing assays based on next-generation sequencing technology (NGS), which can be utilized in comprehensive genomic profiling (CGP) to advance precision oncology. SureSelect cancer assays enable you to detect key classes of somatic variants and assess immuno-oncology biomarkers and homologous recombination deficiency. Explore the benefits such as error-correcting molecular barcodes, convenient enzymatic fragmentation, and minimum sample input; plus, discover how the workflow solution can be configured to meet the specific needs of your laboratory.